What is Geneoscopy?
Geneoscopy Inc. is at the forefront of developing innovative diagnostic tests for gastrointestinal health. Their lead diagnostic leverages stool-derived eukaryotic RNA (seRNA) to identify colorectal cancer and precancerous adenomas. This groundbreaking device has earned Breakthrough Device Designation from the U.S. FDA, highlighting its potential to significantly reduce morbidity associated with colorectal cancer through enhanced adenoma detection. Preliminary trials indicate that Geneoscopy's diagnostic surpasses existing noninvasive screening tests in detecting these critical lesions, positioning the company as a key player in early cancer detection.
How much funding has Geneoscopy raised?
Geneoscopy has raised a total of $217.1M across 4 funding rounds:
Series A
$6.9M
Debt
$150K
Series B
$105M
Series C
$105M
Series A (2019): $6.9M with participation from NT Investments, Cultivation Capital, and Lightchain Capital LLC
Debt (2020): $150K led by PPP
Series B (2021): $105M supported by Nt Investment Academy and Lightchain
Series C (2025): $105M featuring Mercy Health, Granger Management, PETRICHOR Group, Morningside Ventures, Tri Locum Partners, Labcorp, Lightchain Capital, and Bio-Rad Laboratories
Key Investors in Geneoscopy
Nt Investment Academy
Nt Investment Academy operates within the Fitness & Dance Facilities industry, focusing on supporting startups with capital and network resources to navigate hyper growth phases.
Lightchain
Lightchain is a UK-based IT delivery company that specializes in person-focused solutions, helping organizations leverage technology to achieve their goals across various industries.
Mercy Health
Mercy Health, through Harness Health Partners, focuses on developing innovative healthcare solutions and services to maximize employee performance and access to care.
What's next for Geneoscopy?
With the recent influx of $105M in a major strategic investment, Geneoscopy is poised for accelerated growth and further development of its diagnostic technologies. This substantial backing, contributing to a total funding of $217.1M, will likely fuel expanded clinical trials, regulatory submissions, and commercialization efforts. The company's focus on seRNA technology and its FDA Breakthrough Device Designation suggest a strategic trajectory aimed at capturing a significant share of the colorectal cancer screening market, potentially leading to broader applications in gastrointestinal diagnostics.
See full Geneoscopy company page
